MeSH term
Frequency | Condition_Probility | DNA, Neoplasm/analysis | 6 | 0.0 |
Humans | 163 | 0.0 |
Immunohistochemistry | 70 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Tumor Markers, Biological/*metabolism | 6 | 1.0 |
Adolescent | 27 | 0.0 |
Adult | 75 | 0.0 |
Aged | 37 | 0.0 |
English Abstract | 11 | 0.0 |
Female | 86 | 0.0 |
Middle Aged | 59 | 0.0 |
Retrospective Studies | 6 | 0.0 |
Comparative Study | 15 | 0.0 |
Diagnosis, Differential | 43 | 2.0 |
Male | 75 | 0.0 |
Prognosis | 5 | 0.0 |
B-Lymphocytes/metabolism | 2 | 1.0 |
Base Sequence | 4 | 0.0 |
Cell Line | 9 | 0.0 |
Flow Cytometry | 14 | 0.0 |
Molecular Sequence Data | 5 | 0.0 |
Phenotype | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 51 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Tumor Markers, Biological/analysis | 23 | 3.0 |
Antigens, CD/*biosynthesis | 4 | 2.0 |
Cell Adhesion Molecules/*biosynthesis | 4 | 4.0 |
Aged, 80 and over | 10 | 0.0 |
Antigens, CD/analysis | 16 | 0.0 |
Antigens, CD34/analysis | 8 | 1.0 |
Cell Adhesion Molecules/analysis | 13 | 8.0 |
Neoplasm Proteins/analysis | 9 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 4 | 2.0 |
Vimentin/analysis | 6 | 2.0 |
Child | 27 | 0.0 |
Child, Preschool | 14 | 0.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Infant | 14 | 0.0 |
Combined Modality Therapy | 5 | 0.0 |
Desmin/analysis | 2 | 3.0 |
Keratin/analysis | 7 | 3.0 |
Kidney Neoplasms/chemistry/genetics/*pathology/therapy | 2 | 100.0 |
*Proto-Oncogene Proteins | 3 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 5 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 10 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 12 | 0.0 |
Soft Tissue Neoplasms/*genetics/pathology/therapy | 2 | 100.0 |
Tomography, X-Ray Computed | 10 | 1.0 |
Fatal Outcome | 8 | 1.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Cell Adhesion | 3 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 3 | 0.0 |
Antigens, CD/*immunology | 2 | 0.0 |
Cell Adhesion Molecules/*immunology | 2 | 3.0 |
Skin Neoplasms/*immunology/pathology | 2 | 10.0 |
Ubiquitin Thiolesterase | 2 | 1.0 |
Antigens, CD/metabolism | 10 | 1.0 |
Antigens, CD56/metabolism | 2 | 7.0 |
Cell Adhesion Molecules/metabolism | 8 | 3.0 |
*Flow Cytometry | 3 | 1.0 |
Immunophenotyping | 12 | 0.0 |
Biological Markers/analysis | 2 | 0.0 |
Lymphocytes/chemistry/pathology | 2 | 25.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Microscopy, Electron | 7 | 0.0 |
*Neck | 2 | 25.0 |
S100 Proteins/analysis | 3 | 1.0 |
Follow-Up Studies | 5 | 0.0 |
Neoplasms, Fibrous Tissue/chemistry/*pathology | 2 | 28.0 |
Sarcoma/*pathology | 2 | 14.0 |
Animals | 14 | 0.0 |
Antigens, CD/*metabolism | 9 | 1.0 |
Cell Adhesion Molecules/*metabolism | 9 | 3.0 |
Sarcoma, Ewing's/*metabolism | 2 | 40.0 |
Antigens, CD/*analysis | 14 | 1.0 |
Cell Adhesion Molecules/*analysis | 14 | 11.0 |
Cell Division | 3 | 0.0 |
Radiotherapy, Adjuvant | 4 | 4.0 |
Head and Neck Neoplasms/*immunology | 2 | 18.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Cell Size | 2 | 0.0 |
Signal Transduction/physiology | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Neoplasm Proteins/metabolism | 6 | 1.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Antigens, CD/*genetics | 3 | 1.0 |
Blotting, Western | 3 | 0.0 |
Cell Adhesion Molecules/*genetics | 2 | 2.0 |
Signal Transduction | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Transfection | 6 | 0.0 |
Tumor Cells, Cultured | 14 | 0.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
Antibodies, Monoclonal/pharmacology | 3 | 0.0 |
CHO Cells | 2 | 0.0 |
Cells, Cultured | 7 | 0.0 |
Hamsters | 3 | 0.0 |
Jurkat Cells | 9 | 0.0 |
K562 Cells | 2 | 0.0 |
Ligands | 2 | 0.0 |
Carcinoma/chemistry/*pathology | 2 | 20.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Chromosomes, Human, Pair 13/*genetics | 2 | 2.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Treatment Outcome | 6 | 0.0 |
Thymus Gland/metabolism/*pathology | 2 | 66.0 |
*Chromosomes, Human, Pair 18 | 2 | 1.0 |
Karyotyping | 5 | 0.0 |
Lung Neoplasms/secondary | 2 | 2.0 |
Translocation, Genetic/*genetics | 2 | 0.0 |
Immunoenzyme Techniques | 14 | 0.0 |
Oncogene Proteins, Fusion/analysis | 2 | 25.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
Biopsy, Needle | 2 | 0.0 |
Chromosomes, Human, Pair 18 | 2 | 1.0 |
Magnetic Resonance Imaging | 5 | 0.0 |
Translocation, Genetic | 6 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Histocompatibility Antigens Class I/biosynthesis/*metabolism | 2 | 66.0 |
Kinetics | 2 | 0.0 |
Antigens, CD/biosynthesis | 2 | 0.0 |
Cell Adhesion Molecules/biosynthesis | 2 | 2.0 |
Antigens, CD/*physiology | 3 | 0.0 |
Biological Transport | 2 | 0.0 |
Cell Adhesion Molecules/*physiology | 3 | 2.0 |
Antigens, CD34/metabolism | 6 | 2.0 |
Vimentin/metabolism | 5 | 4.0 |
Mice | 6 | 0.0 |
Antigens, CD/immunology | 3 | 0.0 |
Antigens, CD18/immunology | 2 | 11.0 |
Cell Adhesion Molecules/immunology | 2 | 2.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Lymphocyte Function-Associated Antigen-1/immunology | 2 | 7.0 |
Mitotic Index | 2 | 1.0 |
Tumor Markers, Biological/*analysis | 3 | 0.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
Chromosomes, Human, Pair 22 | 2 | 1.0 |
Phosphorylation | 2 | 0.0 |
COS Cells | 2 | 0.0 |
Cell Aggregation/drug effects | 2 | 4.0 |
Cloning, Molecular | 4 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Organ Specificity | 3 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
T-Lymphocytes/*immunology | 4 | 0.0 |
Inhibins/analysis | 2 | 28.0 |
DNA Nucleotidylexotransferase/analysis | 4 | 20.0 |
Neprilysin/analysis | 3 | 5.0 |
Bone Neoplasms/*diagnosis/therapy | 2 | 100.0 |
Chondroblastoma/*diagnosis/therapy | 2 | 100.0 |
Temporal Bone/*pathology/*radiography | 2 | 100.0 |
Exons | 2 | 0.0 |
Oncogene Proteins, Fusion/*genetics | 2 | 1.0 |
Transcription Factors/*genetics | 3 | 0.0 |
*Translocation, Genetic | 3 | 0.0 |
Carcinoma, Small Cell/genetics/metabolism/*pathology | 2 | 100.0 |
Oncogene Proteins, Fusion/genetics | 2 | 2.0 |
Phosphopyruvate Hydratase/analysis | 2 | 2.0 |
Neoplasms, Fibrous Tissue/metabolism/*pathology | 2 | 66.0 |
Pancreatic Neoplasms/metabolism/*pathology | 2 | 6.0 |
Tumor Markers, Biological/metabolism | 10 | 2.0 |
Apoptosis | 3 | 0.0 |
Cell Aggregation | 3 | 2.0 |
Down-Regulation | 3 | 0.0 |
Soft Tissue Neoplasms/chemistry/*pathology | 3 | 21.0 |
Actins/*metabolism | 2 | 0.0 |
Antigens, CD/immunology/*physiology | 2 | 6.0 |
Cell Adhesion Molecules/immunology/*physiology | 3 | 30.0 |
Cell Differentiation | 4 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
CA-15-3 Antigen/analysis | 2 | 3.0 |
Sex Cord-Gonadal Stromal Tumors/*metabolism/pathology | 3 | 75.0 |
Staining and Labeling | 2 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Phosphopyruvate Hydratase/metabolism | 2 | 3.0 |
Keratin/metabolism | 2 | 1.0 |
Mesothelioma/*pathology | 2 | 25.0 |
Amino Acid Sequence | 4 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Cross Reactions | 2 | 0.0 |
Antigens, CD45/analysis | 2 | 0.0 |
Cell Nucleus/ultrastructure | 2 | 1.0 |
Antibodies, Monoclonal/immunology/pharmacology | 2 | 2.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Mitosis | 2 | 0.0 |
Thymus Gland/cytology | 2 | 2.0 |
*Antigens, CD | 2 | 0.0 |
Epitopes/immunology | 2 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Apoptosis/*physiology | 2 | 0.0 |
Myogenin/analysis | 2 | 100.0 |
X Chromosome/genetics | 2 | 1.0 |
Neoplasms, Glandular and Epithelial/metabolism/*pathology | 2 | 100.0 |
